ScholarIQanswers from OpenAlex
Amarin Corporation
FunderResearch funding and supported work
Amarin Corporation is a funder indexed in ScholarIQ from OpenAlex.
What is known about Amarin Corporation?
ScholarIQrecord summary
biopharmaceutical company
How many works does Amarin Corporation have?
ScholarIQindexed works
Amarin Corporation has 1,357 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
What is the OpenAlex record for Amarin Corporation?
ScholarIQopenalex
The OpenAlex for Amarin Corporation is on the source record.
What is the ROR of Amarin Corporation?
ScholarIQror
The ROR for Amarin Corporation is on the source record.
What are the most-cited papers on Amarin Corporation?
ScholarIQmost cited works
Effects of tree nuts on blood lipids, apolipoproteins, and blood pressure: systematic review, meta-analysis, and dose-response of 61 controlled intervention trials
Liana C. Del Gobbo, Michael C. Falk, Robin Feldman, Kara D. Lewis, Dariush Mozaffarian
Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction
Pardeep S. Jhund, Scott D. Solomon, Kieran F. Docherty, Hiddo J.L. Heerspink, Inder S. Anand, Michael Böhm, Vijay Chopra, Rudolf A. de Boer, Akshay S. Desai, Junbo Ge, Masafumi Kitakaze, Bela Merkley, Eileen O’Meara, Morten Shou, С. Н. Терещенко, Subodh Verma, Pham Nguyễn Vinh, Silvio E. Inzucchi, Lars Køber, Mikhail Kosiborod, Felipe A. Martínez, Piotr Ponikowski, Marc S. Sabatine, Olof Bengtsson, Anna Maria Langkilde, Mikaela Sjöstrand, John J.V. McMurray
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups
Kenneth W. Mahaffey, Meg Jardine, Séverine Bompoint, Christopher P. Cannon, Bruce Neal, Hiddo J.L. Heerspink, David M. Charytan, Robert Edwards, Rajiv Agarwal, George L. Bakris, Scott Bull, George Capuano, Dick de Zeeuw, Tom Greene, Adeera Levin, Carol A. Pollock, Tao Sun, David C. Wheeler, Yshai Yavin, Hong Zhang, Bernard Zinman, Norman Rosenthal, Barry M. Brenner, Vlado Perkovic, On behalf of the CREDENCE Study Investigators
Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF
Carly Adamson, Kieran F. Docherty, Hiddo J.L. Heerspink, Rudolf A. de Boer, Kevin Damman, Silvio E. Inzucchi, Lars Køber, Mikhail Kosiborod, Felipe A. Martínez, Mark C. Petrie, Piotr Ponikowski, Marc S. Sabatine, Morten Schou, Scott D. Solomon, Subodh Verma, Olof Bengtsson, Anna Maria Langkilde, Mikaela Sjöstrand, Muthiah Vaduganathan, Pardeep S. Jhund, John J.V. McMurray
Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial
Adrian F. Hernandez, Jacob A. Udell, W. Schuyler Jones, Stefan D. Anker, Mark C. Petrie, Josephine Harrington, Michaela Mattheus, Svenja Seide, Isabella Zwiener, Offer Amir, M. Cecilia Bahit, Johann Bauersachs, Antoni Bayés‐Genís, Yundai Chen, Vijay Chopra, Gemma A. Figtree, Junbo Ge, Shaun G. Goodman, Nina Gotcheva, Shinya Goto, Tomasz Gąsior, Waheed Jamal, James L. Januzzi, Myung Ho Jeong, Yu. M. Lopatin, Renato D. Lópes, Béla Merkely, Puja B. Parikh, Alexander Parkhomenko, Piotr Ponikowski, Xavier Rosselló, Morten Schou, Dragan Šimić, Philippe Gabríel Steg, Joanna Szachniewicz, Peter van der Meer, Dragoş Vinereanu, Shelley Zieroth, Martina Brueckmann, Mikhail Sumin, Deepak L. Bhatt, Javed Butler